Japanese startup Precision Medicine Asia (PREMIA) and US-based Lind have announced the formation of Lind Asia, a strategic joint venture dedicated to revolutionising clinical trial enrollment in the Asia-Pacific (APAC) region.
Lind Asia will serve as the exclusive regional partner for Lind’s artificial intelligence (AI)-powered screening platform by leveraging PREMIA’s deep expertise in managing clinical-genomic databases to accelerate patient eligibility screening for clinical trials. Lind’s platform will be localised for healthcare institutions across Taiwan, Japan, South Korea, Singapore and Australia.
Lind Asia’s platform has three key pillars:
AI-powered patient identification: Analysing structured and unstructured EHR data to identify potentially eligible patients for clinical trials.
Research-ready site network: Building a regional network of partner health systems to support multinational clinical trial enrollment.
Integrated molecular profiling: Incorporating genomic and proteomic data to support biomarker-driven trial matching and targeted therapy development.
“We are dedicated to advancing precision medicine across the Asia-Pacific region by addressing the growing need for accurate, scalable, and automated clinical trial enrollment solutions,” said Wenn Sun, Founder and Managing Partner of PREMIA. “This joint venture combines our regional infrastructure with Lind’s powerful AI platform to drastically improve recruitment efficiency, reduce screen failures, and expedite access to innovative therapies.”
